1. Home
  2. BMEA vs TELA Comparison

BMEA vs TELA Comparison

Compare BMEA & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMEA
  • TELA
  • Stock Information
  • Founded
  • BMEA 2017
  • TELA 2012
  • Country
  • BMEA United States
  • TELA United States
  • Employees
  • BMEA N/A
  • TELA N/A
  • Industry
  • BMEA Biotechnology: Pharmaceutical Preparations
  • TELA Medical/Dental Instruments
  • Sector
  • BMEA Health Care
  • TELA Health Care
  • Exchange
  • BMEA Nasdaq
  • TELA Nasdaq
  • Market Cap
  • BMEA 65.8M
  • TELA 75.2M
  • IPO Year
  • BMEA 2021
  • TELA 2019
  • Fundamental
  • Price
  • BMEA $1.57
  • TELA $1.86
  • Analyst Decision
  • BMEA Strong Buy
  • TELA Strong Buy
  • Analyst Count
  • BMEA 10
  • TELA 4
  • Target Price
  • BMEA $21.00
  • TELA $6.00
  • AVG Volume (30 Days)
  • BMEA 957.5K
  • TELA 61.3K
  • Earning Date
  • BMEA 08-12-2025
  • TELA 08-11-2025
  • Dividend Yield
  • BMEA N/A
  • TELA N/A
  • EPS Growth
  • BMEA N/A
  • TELA N/A
  • EPS
  • BMEA N/A
  • TELA N/A
  • Revenue
  • BMEA N/A
  • TELA $71,217,000.00
  • Revenue This Year
  • BMEA N/A
  • TELA $26.67
  • Revenue Next Year
  • BMEA N/A
  • TELA $22.63
  • P/E Ratio
  • BMEA N/A
  • TELA N/A
  • Revenue Growth
  • BMEA N/A
  • TELA 12.78
  • 52 Week Low
  • BMEA $1.29
  • TELA $0.86
  • 52 Week High
  • BMEA $13.07
  • TELA $4.46
  • Technical
  • Relative Strength Index (RSI)
  • BMEA 37.40
  • TELA 48.47
  • Support Level
  • BMEA $1.72
  • TELA $1.69
  • Resistance Level
  • BMEA $1.75
  • TELA $2.13
  • Average True Range (ATR)
  • BMEA 0.11
  • TELA 0.19
  • MACD
  • BMEA -0.02
  • TELA -0.04
  • Stochastic Oscillator
  • BMEA 9.20
  • TELA 44.56

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About TELA TELA Bio Inc.

TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Share on Social Networks: